Interestingly, our data presented for MeCP2E2 expression in the chronic disease phase (EAE 39–45) (Figure 4B) identify a marked increase in MeCP2E2 mRNA, that correspond more closely as we would have expected with the reported increases in BDNF protein during the same time period (Figure 5A). This evidence concerns the gene BDNF and glycogen storage disease VI.